liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Newcastle Diabetes Centre, Newcastle University, Newcastle upon Tyne, United Kingdom.
Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Department of Endocrinology and Metabolism, Odense, Denmark.
GlaxoSmithKline Research and Development, Greenford, United Kingdom.
Show others and affiliations
2009 (English)In: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 373, no 9681, 2125-2135 p.Article in journal (Refereed) Published
Abstract [en]

Background: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. Methods: In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A 1c (HbA 1c) of 7·9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active control group, n=2227). The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard ratio (HR) non-inferiority margin of 1·20. Analysis was by intention to treat. This study is registered with, number NCT00379769. Findings: 321 people in the rosiglitazone group and 323 in the active control group experienced the primary outcome during a mean 5·5-year follow-up, meeting the criterion of non-inferiority (HR 0·99, 95% CI 0·85-1·16). HR was 0·84 (0·59-1·18) for cardiovascular death, 1·14 (0·80-1·63) for myocardial infarction, and 0·72 (0·49-1·06) for stroke. Heart failure causing admission to hospital or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (HR 2·10, 1·35-3·27, risk difference per 1000 person-years 2·6, 1·1-4·1). Upper and distal lower limb fracture rates were increased mainly in women randomly assigned to rosiglitazone. Mean HbA 1c was lower in the rosiglitazone group than in the control group at 5 years. Interpretation: Addition of rosiglitazone to glucose-lowering therapy in people with type 2 diabetes is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs. Funding: GlaxoSmithKline plc, UK. © 2009 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
Elsevier: Lancet , 2009. Vol. 373, no 9681, 2125-2135 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-107033DOI: 10.1016/S0140-6736(09)60953-3OAI: diva2:721206

Group Author(s): RECORD Study Team

Folke Sjöberg, Linköping University

Available from: 2014-06-03 Created: 2014-06-03 Last updated: 2014-06-03

Open Access in DiVA

No full text

Other links

Publisher's full text
In the same journal
The Lancet
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 34 hits
ReferencesLink to record
Permanent link

Direct link